[Visceral leishmaniasis: a new oral treatment?].
Minodier
P
P
Nicaise
C
C
Gire
C
C
Garnier
J M
JM
D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine
Leishmaniose viscérale: un nouveau traitement par voie orale?